Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1.
CRISPR-Cas9 systems are attaining greater power and precision, and alternatives such as homing nuclease and “gene writer” systems are becoming more capable, too.